0000939767-17-000003.txt : 20170105 0000939767-17-000003.hdr.sgml : 20170105 20170105202514 ACCESSION NUMBER: 0000939767-17-000003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170103 FILED AS OF DATE: 20170105 DATE AS OF CHANGE: 20170105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS, INC. CENTRAL INDEX KEY: 0000939767 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043257395 STATE OF INCORPORATION: DE FISCAL YEAR END: 0102 BUSINESS ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508377000 MAIL ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS INC DATE OF NAME CHANGE: 20000207 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lamb Peter CENTRAL INDEX KEY: 0001387306 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30235 FILM NUMBER: 17512636 MAIL ADDRESS: STREET 1: PO BOX 511, 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94083-0511 4 1 wf-form4_148366589849602.xml FORM 4 X0306 4 2017-01-03 0 0000939767 EXELIXIS, INC. EXEL 0001387306 Lamb Peter C/O EXELIXIS, INC. 210 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP, Scientific Strategy & CSO Common Stock 2017-01-03 4 M 0 10000 4.42 A 83600 D Common Stock 2017-01-03 4 M 0 60000 5.96 A 143600 D Common Stock 2017-01-03 4 S 0 67600 14.63 D 76000 D Common Stock 2017-01-03 4 S 0 2400 15.27 D 73600 D Common Stock 16024 I By 401(k) Option (right to buy) 4.42 2017-01-03 4 M 0 10000 0 D 2010-02-26 2019-02-25 Common Stock 10000.0 0 D Option (right to buy) 5.96 2017-01-03 4 M 0 60000 0 D 2010-09-01 2019-08-31 Common Stock 60000.0 15000 D Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 27, 2016. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.24 to $15.23. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.24 to $15.32. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Represents 16,024 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of January 3, 2017. The option, representing the right to purchase a total of 25,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 26, 2013. The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 1, 2013. /s/ Jeffrey J. Hessekiel, Attorney in Fact 2017-01-05